Abbott Laboratories (ABT)
Health Care7 articles
Price chart
Abbott Laboratories (ABT) overview
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Abbott Laboratories trades on the NYSE under the ticker symbol ABT. As of the most recent market data, the stock was priced around $100.68, up 1.87% on the session.
Over the past 52 weeks, ABT has traded between $81.97 and $137.49. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 28.2, a common gauge of how richly the market prices the company's earnings. Abbott Laboratories also pays a dividend, currently yielding around 2.50%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch ABT
As one of the larger companies in the Health Care sector, Abbott Laboratories is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch ABT for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest ABT news
Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
A federal judge ruled that Abbott Laboratories (ABT) must face a class-action lawsuit regarding allegations it misled consumers about PediaSure Grow & Gain drinks being 'clinically proven' for children's growth. The lawsuit claims the marketing could mislead consumers into interpreting growth as height gain, while using labels suggesting weight gain. Plaintiff Joanne Noriega alleges her grandson remained short after a year of daily use. Abbott maintains its labeling is appropriate and evidence-based, stating PediaSure supports children's growth and development.
Read More: Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
Abbott Laboratories (ABT) is set to report its second-quarter earnings on July 16. In Q1, the company's medical device revenue reached approximately $5.5 billion, contributing about 50% of total sales. The FreeStyle Libre platform alone generated roughly $2 billion in sales, with over 7 million users globally. The cardiovascular segment also showed growth, with $578 million in revenue. These figures highlight Abbott's diverse business structure and position in the medical device market, which could impact investor decisions leading up to the earnings announcement.
Read More: Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
Adeptus Biotechnologies Stock Rating Maintained by BTIG
BTIG has reiterated its stock rating on Adeptus Biotechnologies, following the company's strategic decision to split its business. This move is intended to focus on core areas and potentially unlock shareholder value. No specific numbers related to financial metrics or projected impacts are available in the report. The decision is positioned to strengthen Adeptus's market presence and operational efficiency, impacting investor sentiment positively.
Read More: Adeptus Biotechnologies Stock Rating Maintained by BTIG
Abbott Laboratories (ABT) Director Daniel Starks Buys $926,537 in Shares
Daniel Starks, a director at Abbott Laboratories (ABT), purchased $926,537 worth of shares. This transaction signifies his confidence in the company's future performance. The noteworthy investment could influence investor perception and potentially affect share prices. Transactions of this scale often draw attention, as they may indicate insider optimism about the company's current and upcoming market conditions.
Read More: Abbott Laboratories (ABT) Director Daniel Starks Buys $926,537 in Shares
Abbott Labs (ABT) stock price target cut to $120 by Benchmark
Benchmark has reduced its price target for Abbott Labs (ABT) stock to $120. This change reflects a re-evaluation of the company's valuation metrics. Such a downgrade can influence market perceptions and potentially impact stock performance. It is essential to monitor how this adjustment affects trading volume and investor sentiment moving forward.
Read More: Abbott Labs (ABT) stock price target cut to $120 by Benchmark
Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
Abbott Laboratories (ABT) has seen its stock decline 20% this year, influenced by a recent earnings report and ongoing legal issues concerning its special baby formula. Jim Cramer highlighted that Abbott recently acquired Exact Sciences for approximately $21 billion, a deal representing a 51% premium over its prior trading price, marking the largest healthcare merger in two years. Despite this acquisition, Abbott's stock has fallen more than $6 in two days following the announcement. Investors are cautious and awaiting additional insights during the upcoming earnings call to assess future growth potential.
Read More: Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
Abbott (ABT) Jury Orders $53 Million Payment in Formula Case
A jury has ordered Abbott (ABT) to pay $53 million following a trial related to preterm infant formula. This ruling could have significant implications for Abbott's financial position and market perception, especially in terms of product liability risks. The outcome of the trial may influence future litigation and customer trust in the company's products. Market analysts may watch for potential impacts on Abbott's stock price and overall valuation as a result.
Read More: Abbott (ABT) Jury Orders $53 Million Payment in Formula CaseMore Health Care stocks
Frequently asked questions
Is Abbott Laboratories in the S&P 500?
Yes. Abbott Laboratories (ABT) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is ABT in?
Abbott Laboratories is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest ABT news?
This page collects recent Abbott Laboratories (ABT) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Abbott Laboratories's stock price?
As of the most recent market data, Abbott Laboratories (ABT) traded at approximately $100.68. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is ABT's P/E ratio?
ABT trades at a trailing price-to-earnings ratio of about 28.2. The P/E ratio compares a company's share price to its earnings per share.